Drug Wholesaler Alleges Pay-For-Delay Scheme By Novartis

Law360 (June 29, 2018, 8:55 PM EDT) -- A defunct Illinois drug distribution company filed putative class antitrust allegations against Novartis Pharmaceuticals Corp. and Par Pharmaceutical Inc. on Friday, alleging in New York federal court that the pair cooked up a pay-for-delay scheme for Novartis' high blood pressure drug Exforge.

FWK Holdings Co., the successor to the Frank W. Kerr Co., alleged that Novartis and Par agreed for Par to wait to bring a generic version of Exforge to market in exchange for six months of exclusivity with the drug on the market. The complaint noted that Novartis never sued Par for patent infringement, and argued that Novartis knew...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!